The useful question is what changes for users, developers or buyers, and whether the announcement stays industry context or becomes something people can actually use.

Johnson & Johnson received FDA approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform, which integrates radiofrequency and pulsed field energy delivery into a single catheter. The platform builds on the existing THERMOCOOL SMARTTOUCH SF system, which has treated over one million patients in the U.S. and is designed to enhance procedural versatility for treating complex cardiac cases.

The DE STSF Platform is compatible with the CARTO ecosystem, providing advanced mapping, imaging, and PF Index guidance to support precise energy delivery and reproducible workflows. Electrophysiologists can now choose between RF or PF energy based on patient anatomy and procedural requirements, offering greater flexibility in treatment planning.

Michael Bodner, Company Group Chair of Electrophysiology & Neurovascular at Johnson & Johnson MedTech, highlighted the platform’s role in expanding treatment options for increasingly complex cardiac cases. The company plans to initiate commercial rollout in the U.S. this summer, following successful European introduction.

Dr. Dhanunjaya Lakkireddy, Executive Medical Director at The Kansas City Heart Rhythm Institute, noted the platform’s ability to adapt to diverse anatomies and treatment goals. The first U.S. procedures are expected to begin this summer as part of a phased commercial launch.